1. Comparative Efficacy, Safety and Pharmacokinetics of Verapamil SR vs Verapamil IR in Hypertensive Patients

   • Nery T. Fuenmayor
   • Barbara M. Faggin
   • Luigi X. Cubeddu

   OriginalPaper 27 October 2012 Pages: 1 - 11

2. Use of Ambulatory Blood Pressure Monitoring in the Management of Antihypertensive Therapy

   • Jean-Michel Mallion
   • Anne Maitre
   • Frederic Tremel

   OriginalPaper 27 October 2012 Pages: 12 - 16

3. Ambulatory Blood Pressure Monitoring

   • G. Mancia
   • S. Omboni
   • A. Villani

   OriginalPaper 27 October 2012 Pages: 17 - 22

4. Calcium Overload — An Important Cellular Mechanism in Hypertension and Arteriosclerosis

   • G. Fleckenstein-Grün
   • M. Frey
   • A. Fleckenstein

   OriginalPaper 27 October 2012 Pages: 23 - 30

5. Discussion: Section 1

   OriginalPaper 27 October 2012 Pages: 31 - 32

6. Secondary Prevention with Calcium Antagonists after Acute Myocardial Infarction

   • Jørgen Fischer Hansen

   OriginalPaper 27 October 2012 Pages: 33 - 43

7. Cardiac Hypertrophy and Aortic Compliance after Calcium Channel Antagonism in Hypertension

   • B. M. Pannier
   • J. L. Tual
   • M. E. Safar

   OriginalPaper 27 October 2012 Pages: 44 - 47

8. Regional Myocardial Blood Flow and Coronary Reserve in Hypertensive Patients

   • O. Parodi
   • D. Neglia
   • L. Donato

   OriginalPaper 27 October 2012 Pages: 48 - 55

9. The J-Curve

   • M. Luque-Otero
   • C. Fernandez-Pinilla

   OriginalPaper 27 October 2012 Pages: 56 - 60

10. Is Salt Restriction Necessary in Hypertensive Patients Treated with Calcium Antagonists?

    • J. Redon

    OriginalPaper 27 October 2012 Pages: 61 - 65

11. Discussion: Section 2

    OriginalPaper 27 October 2012 Pages: 66 - 66

12. Risk-Benefit Aspects of Antihypertensive Drugs

    • H. Holzgreve
    • M. Middeke

    OriginalPaper 27 October 2012 Pages: 67 - 73

13. Swiss Hypertension Treatment Programme with Verapamil and/or Enalapril in Diabetic Patients

    • Claudia Fevrier
    • Paolo Ferrari
    • Walter F. Riesen

    OriginalPaper 27 October 2012 Pages: 74 - 84

14. The Effect of Sustained Release Verapamil on Glucose Metabolism in Patients with Non-Insulin-Dependent Diabetes Mellitus

    • J. Lyngsøe
    • M. Busch Sørensen
    • J. Juul Holst

    Short Communication 27 October 2012 Pages: 85 - 87

15. Effects of Treatment with Verapamil SR and Captopril on the Lipid Profile of Hypertensive Patients

    • Maria Catalano
    • Carlo Cislaghi
    • Arnaldo Libretti

    OriginalPaper 27 October 2012 Pages: 88 - 93

16. Sodium Intake Does Not Influence the Effect of Verapamil in Hypertensive Patients with Mild Renal Insufficiency

    • Luis M. Ruilope
    • Maria C. Casal
    • Jose L. Rodicio

    OriginalPaper 27 October 2012 Pages: 94 - 98

17. Is Renal Protection with Calcium Antagonists Possible?

    • P. García-Cosmes
    • A. Mortezo
    • J. F. Macías-Núñez

    OriginalPaper 27 October 2012 Pages: 99 - 102

18. Discussion: Section 3

    OriginalPaper 27 October 2012 Pages: 103 - 104

19. Use of Cell Culture for Optimisation of Direct Antiatherogenic Therapy with Verapamil

    • A. N. Orekhov
    • E. M. Pivovarova
    • V. V. Tertov

    OriginalPaper 27 October 2012 Pages: 105 - 110

20. Vascular Calcium Overload

    • Jeffrey Atkinson

    OriginalPaper 27 October 2012 Pages: 111 - 118

21. Arterial Calcinosis, Chronic Renal Failure and Calcium Antagonism

    • S. J. Marchais
    • A. P. Guerin
    • G. M. London

    OriginalPaper 27 October 2012 Pages: 119 - 122

22. Can the Coronary Atherosclerotic Process Be Influenced by Calcium Antagonists?

    • G. Kober
    • W. Schneider
    • M. Kaltenbach

    OriginalPaper 27 October 2012 Pages: 123 - 127

23. Preliminary Clinical Experience with Calcium Antagonists in Atherosclerosis

    • B. Magnani
    • C. Dal Palù
    • Verapamil in Hypertension Atherosclerosis Study Investigators

    OriginalPaper 27 October 2012 Pages: 128 - 133

24. Discussion: Section 4

    OriginalPaper 27 October 2012 Pages: 134 - 134

25. Quality of Life in the Treatment of Hypertension

    • Astrid Fletcher
    • Christopher Bulpitt

    OriginalPaper 27 October 2012 Pages: 135 - 140

26. Does a Reduction in Left Ventricular Hypertrophy Reduce Cardiovascular Morbidity and Mortality?

    • Franz H. Messerli
    • Federico Soria

    OriginalPaper 27 October 2012 Pages: 141 - 146

27. Choosing the Correct Drug for the Individual Hypertensive Patient

    • L. H. Opie

    OriginalPaper 27 October 2012 Pages: 147 - 155

28. Discussion: Section 5

    OriginalPaper 27 October 2012 Pages: 156 - 157